Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 01:22:19 Source:sportViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:DR MARTIN SCURR: How losing your hearing may cause dementia
Next:Burglar hurled stolen mobile phones at police from the top of 60ft high roof during nine
You may also like
- China's first intelligent offshore drilling platform installed
- City set to enjoy a bonanza of tourist attractions
- Xi Stresses Accelerated Efforts to Build Leading Country in Education
- Xi Focus: Encouraging Sci
- Target to lower prices on basic goods in response to inflation
- Peng Liyuan Meets with DRC's First Lady
- Wintering birds return to China's largest recovering freshwater lake
- Intl beer festival to open in Qingdao WCNA
- College baseball notebook: Conference tournaments to decide NCAA automatic bids and many at